A UK innovation agency, the Technology Strategy Board, has awarded Team Consulting a grant to fund an 8-month feasibility test of its Occoris inhaler “engine” technology, the company said. According to Team, the Occoris engine, approximately the size of a pea, can deliver API-only dry powder formulations accurately and repeatably.
The feasibility testing funded by the grant will involve a partnership with a manufacturer “to conduct further testing and refinement of the Occoris design to demonstrate its potential for high volume manufacturability and commercial viability.”
Team Consulting Head of Respiratory Drug Delivery David Harris commented, “To have Occoris recognized as one of the most exciting medtech innovations in the UK is a huge honor. Ultimately our goal is to help patients by creating a readily available low cost inhaler that is easier to use, more accurate and more reliable than existing devices. The grant we have received from the Technology Strategy Board is a massive boost to help us make that a reality.”
Read the Team Consulting press release.
